No insider purchase over the last 90 days. The latest, by Krzysztof Miszewski, was filed 06 Jul 2026.
+2 other insiders
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate Neuca Strong Buy (bullish), based on 5 analysts. Average price target: PLN 963.64.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 40 declarations
Neuca is a Polish healthcare and pharma company listed on the Warsaw stock exchange with a market capitalisation of PLN 3.1 billion, and 60.6% of the capital is held by insiders. The 40 filings in the record cover trades from September 19, 2022 to September 14, 2026, and all fall in the last twelve months, with 36 in 2026 against 4 in 2025.
Sales number 25, worth EUR 6.0 million (median EUR 219,749), against 10 purchases, 9 of them with an amount, worth EUR 3.6 million (median EUR 199,830): 29% purchases among open-market trades. Daniel Wojtkiewicz, vice president of the management board, sold EUR 1,192,945 on September 14, 2026 and bought EUR 699,109 on May 13, 2026. Grzegorz Dzik, president of the management board, sold EUR 533,376 on September 4, 2026, and Julita Czyzewska, vice president of the management board, EUR 462,668 on November 28, 2025.
The largest purchase is Piotr Sucharski's, president of the management board: EUR 1,203,360 on December 8, 2025; Julita Czyzewska bought EUR 704,751 on January 13, 2026. From May 5 to May 13, 2026, 2 insiders bought for EUR 898,939. Krzysztof Miszewski is the most active with 10 filings, 5 purchases and 5 sales. Median publication delay: 1 day.